PPA
CKPT

Parametric Portfolio Associates’s Checkpoint Therapeutics CKPT Stock Holding History

Parametric Portfolio Associates’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,470
Closed -$43K – 3612
2021
Q2 		$43K Sell
1,470
-719
-33% -$19.9K ﹤0.01% 3541
2021
Q1 		$69K Sell
2,189
-190
-8% -$6.37K ﹤0.01% 4003
2020
Q4 		$63K Buy
2,379
+556
+30% +$14.1K ﹤0.01% 3927
2020
Q3 		$49K Sell
1,823
-188
-9% -$4.51K ﹤0.01% 3866
2020
Q2 		$40K Buy
+2,011
New +$36.6K ﹤0.01% 3877

Other funds holding CKPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SAG
Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

Parametric Portfolio Associates's CKPT Position: Q3 2021 in Review

Parametric Portfolio Associates sold out of Checkpoint Therapeutics (CKPT) in Q3 2021, closing a stake of 1,470 shares — an estimated $43K sold.

Parametric Portfolio Associates first reported a position in CKPT in Q2 2020 and held it in 5 quarters. The position peaked at $69K in Q1 2021. 67 funds tracked by Wall St. Rank hold CKPT as of Q3 2021.

  • Parametric Portfolio Associates reported no remaining Checkpoint Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 1,470 Checkpoint Therapeutics shares in Q3 2021, an estimated $43K.
  • Parametric Portfolio Associates first reported a position in Checkpoint Therapeutics in Q2 2020 and held it in 5 quarters.
  • Parametric Portfolio Associates's Checkpoint Therapeutics position peaked at $69K in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q3 2021.

Based on Parametric Portfolio Associates's 13F filing for Q3 2021, filed 15 Nov 2021.